The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the
progress of several vaccines and antivirals through clinical trials, including the replication …

Ebola virus (EBOV) is a significant human pathogen that presents a public health concern as
an emerging/re-emerging virus and as a potential biological weapon. Substantial progress …

The devastating Ebola virus (EBOV) outbreak in West Africa in 2013–2016 has flagged the
need for the timely development of vaccines for high-threat pathogens. To be better …

The Ebola virus (EBOV) epidemic in West Africa increased the focus on vaccine
development against this hemorrhagic fever–causing pathogen, and as a consequence …

In response to the Ebola virus (EBOV) crisis of 2013–2016, a recombinant vesicular
stomatitis virus (VSV)–based EBOV vaccine was clinically tested (NCT02283099). A single …

Ebola virus (EBOV) infections cause lethal hemorrhagic fever in humans, resulting in up to
90% mortality. EBOV outbreaks are sporadic and unpredictable in nature; therefore, a …

Abstract For Ebola virus (EBOV), 4 different species are known: Zaire, Sudan, Cô te d'Ivoire,
and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed …

BACKGROUND: The 2013–2016 Ebola virus outbreak in West Africa was the most
widespread in history. In response, alive attenuated recombinant vesicular stomatitis virus …

Background The replication-competent recombinant vesicular stomatitis virus (rVSV)–based
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …

Background The worst Ebola virus disease (EVD) outbreak in history has resulted in more
than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an …